<DOC>
	<DOCNO>NCT01463683</DOCNO>
	<brief_summary>This study evaluate immunogenicity , safety , tolerability 2XP HEPTAVAX™-II compare 1XP HEPTAVAX™-II healthy Japanese young adult .</brief_summary>
	<brief_title>Modified Process Hepatitis B Vaccine Japanese Young Adults ( V232-062 )</brief_title>
	<detailed_description>2XP HEPTAVAX™-II manufacture use modified process composition amorphous aluminum hydroxyphosphate sulfate adjuvant modify increase phosphate content approximately 2-fold . Thus modified process HEPTAVAX™-II refer 2XP HEPTAVAX™-II .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>To receive first study vaccination , Participants meet inclusion criterion . Participants provide write informed consent trial . The Participant may also provide consent Future Biomedical Research . However , Participant may participate main trial without participate Future Biomedical Research . Participant Japanese male female , 20 35 year age day first study vaccination . Participant determine general good health base medical history take Day 1 prior receive first injection vaccine . Any underlying chronic illness must document stable condition . For female , negative urine pregnancy test prior vaccination Day 1 . To receive first study vaccination , Participants exclusion criterion . For item asterisk ( * ) , Participant meet exclusion criterion , visit may reschedule time criterion meet . Participant history previous hepatitis B infection . Participant history vaccination hepatitis B vaccine . *Participant recent ( ≤72 hour ) history febrile illness ( oral temperature ≥ 37.8°C ) . Participant know suspected hypersensitivity component HEPTAVAX™II vaccine latex ( e.g. , aluminum , yeast ) . Participant recent administration ( within 3 month prior first injection study vaccine ) hepatitis B immune globulin ( HBIG ) , serum immune globulin , bloodderived product , expect require bloodderived product study . *Participant receive licensed inactivated vaccine within 14 day prior license live vaccine within 28 day prior first injection study vaccine . Participant receive investigational drug investigational vaccine within 3 month prior first injection study vaccine . Use immunosuppressive therapy . Participants corticosteroid exclude receive expect receive , period 4 week prior enrollment 6 week post vaccination , systemic dos great required physiological replacement , i.e. , &gt; 5 mg prednisone ( equivalent ) per day &gt; 2 week ( except use topical inhalation steroid therapy ) . Pregnant woman , nurse mother , woman plan become pregnant within study period . Women childbearing age employ acceptable method contraception study ( e.g. , condom , diaphragm , oral contraceptive , Intrauterine Device ( IUD ) , hormonal implant consider acceptable ) . Participant condition , , opinion investigator , might interfere evaluation study objective . Participant coagulation disorder contraindicate intramuscular injection . Participant immunocompromised condition ( Human Immunodeficiency Virus ( HIV ) positive , leukemia , lymphoma , cancer disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>